IllnessDiabetes mellitus, neonatal; differential diagnosis
Summary
Comprehensive differential diagnostic panel for Aicardi-Goutières syndrome cotaining 24 guideline-curated core genes and altogether 40 curated genes according to the clinical signs
46,8 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
NGS +
[Sanger]
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
ABCC8 | 4746 | NM_000352.6 | AD, AR | |
EIF2AK3 | 3351 | NM_004836.7 | AR | |
FOXP3 | 1296 | NM_014009.4 | XLR | |
GATA4 | 1329 | NM_002052.5 | AD | |
GATA6 | 1788 | NM_005257.6 | AD | |
GCK | 1398 | NM_000162.5 | AD, AR | |
GLIS3 | 2328 | NM_152629.4 | AR | |
HNF1A | 1896 | NM_000545.8 | AD | |
HNF1B | 1674 | NM_000458.4 | AD | |
HNF4A | 1359 | NM_175914.4 | AD | |
IER3IP1 | 249 | NM_016097.5 | AR | |
INS | 333 | NM_000207.3 | AD, AR | |
KCNJ11 | 1173 | NM_000525.4 | AD | |
NEUROD1 | 1071 | NM_002500.5 | AR | |
NEUROG3 | 645 | NM_020999.4 | AR | |
NKX2-2 | 822 | NM_002509.4 | AR | |
PAX6 | 1269 | NM_000280.5 | AR | |
PDX1 | 852 | NM_000209.4 | AR | |
PTF1A | 987 | NM_178161.3 | AR | |
RFX6 | 2787 | NM_173560.4 | AR | |
SLC19A2 | 1494 | NM_006996.3 | AR | |
SLC2A2 | 1575 | NM_000340.2 | AR | |
WFS1 | 2673 | NM_006005.3 | AD, AR | |
BSCL2 | 1197 | NM_032667.6 | AR | |
CISD2 | 408 | NM_001008388.5 | AR | |
EIF2B1 | 918 | NM_001414.4 | AD | |
INSR | 4149 | NM_000208.4 | AD | |
PLAGL1 | 1392 | NM_001080951.3 | Meth | |
ZFP57 | 1611 | NM_001109809.5 | AD, AR |
Informations about the disease
Neonatal diabetes mellitus occurs in two different forms, permanent or transient. Permanent neonatal diabetes mellitus begins in the first six months of life and persists throughout life due to insulin deficiency. In these patients, intrauterine growth retardation occurs, and the infants suffer from dehydration and failure to thrive. In some cases, developmental delay and epilepsy are observed, and a few have pancreatic malformations. One third of these patients have mutations in the KCNJ11 gene, and 20% each show mutations in the ABCC8 or INS genes. If the disorder is caused by mutations in the KCNJ11 or INS genes, autosomal dominant inheritance is present. However, in 90% of cases, the disease arises from new mutations in these genes. When diabetes is caused by mutations in the ABCC8 gene, it can be either autosomal dominantl or recessively inherited. Less commonly, the disease is caused by mutations in other genes with autosomal recessive inheritance.
6q24-related transient neonatal diabetes mellitus is a form that occurs in infants, and it is also characterised by insulin deficiency hyperglycaemia. These patients suffer from severe intrauterine growth retardation, and the infants are usually dehydrated by the first week of life. Symptoms subside over time and generally disappear by 3-18 months of age. However, diabetes can recur, especially during childhood illness or during pregnancy, thus up to 50% of those affected will still develop permanent diabetes later in life. Other features of 6q24-related diabetes include macroglossia, umbilical hernias, brain, heart or kidney malformations, muscle hypotonia, deafness and developmental delay. This form of diabetes is caused by overexpression of genes in the affected chromosomal region due to disturbed genomic imprinting - including of the PLAGL1 gene. About 40% of cases are caused by paternal uniparental disomy, another 40% by paternal duplications and the remaining 20% by maternal hypomethylation, half of which are caused by mutations in the ZFP57 gene. Thus, most cases of 6q24-related transient neonatal diabetes are not inherited, yet ZFP57 mutations cause an autosomal recessive pattern. Since the overall DNA diagnostic yield is 80% together in permanent and transient neonatal diabetes, a negative molecular genetic result does not exclude the clinical diagnosis.
References: https://www.ncbi.nlm.nih.gov/books/NBK1447/
https://www.ncbi.nlm.nih.gov/books/NBK1534/
- Alias: Neonatal diabetes mellitus (NDM)
- Allelic: Cataract 41 (WFS1)
- Allelic: Deafness, AD 6/14/38 (WFS1)
- Allelic: Diabetes mellitus, gestational (GCK)
- Allelic: Diabetes mellitus, insulin-dependent (HNF1A)
- Allelic: Diabetes mellitus, insulin-dependent, 2 (INS)
- Allelic: Diabetes mellitus, insulin-dependent, 20 (HNF1A)
- Allelic: Diabetes mellitus, noninsulin-dependent (ABCC8, HNF1B, HNF4A, SLC2A2)
- Allelic: Diabetes mellitus, noninsulin-dependent, 2 (HNF1A)
- Allelic: Diabetes mellitus, noninsulin-dependent, association with (WFS1)
- Allelic: Diabetes mellitus, noninsulin-dependent, late onset (GCK)
- Allelic: Diabetes mellitus, type 1 (INS)
- Allelic: Diabetes mellitus, type 2, susceptibility to (KCNJ11)
- Allelic: Diabetes mellitus, type II, susceptibility to (PDX1)
- Allelic: Diarrhea 4, malabsorptive, congenital (NEUROG3)
- Allelic: Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young (HNF4A)
- Allelic: Hepatic adenoma, somatic (HNF1A)
- Allelic: Hyper-IgE recurrent infection syndrome (STAT3)
- Allelic: Hyperinsulinemic hypoglycemia, familial, 1 (ABCC8)
- Allelic: Hyperinsulinemic hypoglycemia, familial, 2 (KCNJ11)
- Allelic: Hyperinsulinemic hypoglycemia, familial, 3 (GCK)
- Allelic: Hypoglycemia of infancy, leucine-sensitive (ABCC8)
- Allelic: MODY, type II (GCK)
- Allelic: MODY, type III (HNF1A)
- Allelic: MODY, type IV (PDX1)
- Allelic: MODY, type VI (NEUROD1)
- Allelic: MODY, type X (INS)
- Allelic: Neuropathy, distal hereditary motor, type VC (BSCL2)
- Allelic: Silver spastic paraplegia syndrome (BSCL2)
- Allelic: Thiamine-responsive megaloblastic anemia syndrome (SLC19A2)
- Allelic: Vissers-Bodmer syndrome (CNOT1)
- Allelic:MODY, type I (HNF4A)
- Asphyxiating thoracic dystrophy syndrome + infantile‐onset diabetes [panelapp] (PDIA6)
- Autoimmune disease, multisystem, infantile-onset, 1 (STAT3)
- Congenital generalised lipodystrophy, severe insulin resistance + diabetes [panelapp] (BSCL2)
- Currarino syndrome (MNX1)
- Diabetes mellitus, neonatal, with congenital hypothyroidism (GLIS3)
- Diabetes mellitus, permanent neonatal (ABCC8, GCK, INS)
- Diabetes mellitus, permanent neonatal, with neurologic features (KCNJ11)
- Diabetes mellitus, transient neonatal (KCNJ11)
- Diabetes mellitus, transient neonatal 2 (ABCC8)
- Diabetes, mellitus, insulin-dependent, susceptibility to, 10 (IL2RA)
- Diabetes, permanent neonatal (KCNJ11)
- Encephalopathy, progressive, with/-out lipodystrophy (BSCL2)
- Fanconi-Bickel syndrome (SLC2A2)
- Holoprosencephaly 12, with or without pancreatic agenesis (CNOT1)
- Immunodeficiency 41 with lymphoproliferation + autoimmunity (IL2RA)
- Immunodysregulation, polyendocrinopathy, enteropathy, XL, IPEX (FOXP3)
- Leukoencephalopathy with vanishing white matter 1, +/- ovarian failure (EIF2B1)
- Lipodystrophy, congenital generalized, type 1 (AGPAT2)
- Lipodystrophy, congenital generalized, type 2 (BSCL2)
- MEHMO [Mental retard., Epilepsy, Hypogonadism/-genitalism, Microcephaly, Obesity] syndrome (EIF2S3)
- Microcephaly, epilepsy + diabetes syndrome (IER3IP1)
- Microcephaly, epilepsy + diabetes syndrome 2 (YIPF5)
- Mitchell-Riley syndrome, includes neonatal diabetes (RFX6)
- Neonatal diabetes + generalised lipodystrophy [panelapp] (BSCL2)
- Neonatal diabetes mellitus [MONDO:0016391, panelapp] (ONECUT1)
- Neonatal diabetes mellitus [MONDO:0016391, panelapp] (ZNF808)
- Neonatal diabetes mellitus [MONDO:0016391] (IL2RA)
- Neonatal diabetes, pancreatic agenesis and/or congenital heart defects (GATA4)
- ONECUT1-associated neonatal diabetes [panelapp] (ONECUT1)
- Pancreatic agenesis 1 (PDX1, PTF1A)
- Pancreatic agenesis [MONDO:0009832, panelapp] (ZNF808)
- Pancreatic agenesis and congenital heart defects (GATA6)
- Renal cell carcinoma (HNF1A, HNF1B)
- Renal cysts and diabetes syndrome (HNF1B)
- Wolcott-Rallison syndrome (EIF2AK3)
- Wolfram syndrome 1 (WFS1)
- Wolfram-like syndrome, AD (WFS1)
- AD
- AR
- Meth
- XLR
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.